Kenox Pharmaceuticals Achieves Clinical Manufacturing Readiness

Expands GMP analytical testing capabilities to support nasal and inhaled therapies

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

Kenox Pharmaceuticals Inc., a contract development and manufacturing organization (CDMO) focused on orally inhaled and nasal drug products, has announced that it is now fully Clinical Manufacturing Ready. The company has also expanded its GMP analytical testing capabilities, including in vitro bioequivalence (IVBE) testing, to support innovators advancing nasal and inhaled therapies.

Why it matters

Kenox's integrated capabilities, from feasibility through clinical supply and bioequivalence support, help de-risk development and shorten timelines for pharmaceutical companies working on nasal and inhaled drug products. This is particularly important for programs targeting central nervous system indications, pulmonary conditions, pain management, and rare diseases.

The details

Kenox supports small-scale fill–finish operations for small molecules, peptides, and biologics, with batch sizes ranging from hundreds to a few thousand units, ideally suited for Phase I and Phase II clinical trials. The company's specialized expertise spans nebulizers, soft mist inhalers (SMIs), nasal sprays, and dry powder inhalers (DPIs), supported by robust analytical and formulation development, comprehensive OINDP performance testing, IVBE studies, and regulatory support packages.

  • Kenox Pharmaceuticals Inc. announced its clinical manufacturing readiness on March 4, 2026.

The players

Kenox Pharmaceuticals Inc.

A fast-growing contract development and manufacturing organization (CDMO) dedicated exclusively to Orally Inhaled and Nasal Drug Products (OINDPs) and Ophthalmic Drug Products.

Sitaram Velaga

Founder, President, and CEO of Kenox Pharmaceuticals Inc.

Got photos? Submit your photos here. ›

What they’re saying

“Achieving clinical manufacturing readiness is a major milestone for Kenox. Our goal has always been to help partners reach the clinic faster and with greater confidence. By integrating development, GMP testing—including IVBE—and clinical manufacturing under one roof, we are significantly de‑risking early‑stage programs while delivering the speed, flexibility, and quality that innovative OINDP products demand.”

— Sitaram Velaga, Founder, President, and CEO (PRNewswire)

What’s next

Kenox is positioned to support programs across a broad range of therapeutic areas, including CNS indications leveraging nose‑to‑brain delivery, pulmonary conditions, pain management, and rare diseases. The company is welcoming partnership discussions to help accelerate time to clinic and time to market for innovative nasal and inhaled drug products.

The takeaway

Kenox's expanded capabilities in clinical manufacturing and analytical testing for orally inhaled and nasal drug products will help pharmaceutical companies de-risk development and shorten timelines for bringing these innovative therapies to patients, particularly in areas of high unmet medical need.